The plaintiff, a woman who'd used the company's Panorama test during a pregnancy, is asking the court to certify her case a class action.
The company has signed a deal with Aarhus University that gives it access to a 40,000-sample biobank of patients who were screened for colorectal cancer.
After fighting through some headwinds in 2021, the company said it will show off new data and tests in the next couple of years.
The firm is aiming to create pan-organ transplant services that connect patients to doctors throughout the transplant and recovery process.
The molecular diagnostics company reported $75.6 million in revenues for the quarter and said testing service revenues rose 46 percent year over year.
In a separate case in which CareDx and Natera are suing each other for false advertising, a court has set a trial date in late October.
The companies are creating a platform that will test for both anti-nucleocapsid and anti-spike antibodies in the same reaction.
The point-of-care system can detect SARS-CoV-2 in unprocessed patient saliva in about an hour, according to the researchers.
The company hopes to complete the trial in early 2022 and submit data to the FDA for approval of its assay, which could compete with Exact Sciences' Cologuard.
Synthetic biology and CRISPR have enabled researchers to develop wearable sensors that can detect a variety of viruses and bacteria, including SARS-CoV-2.